FDA Recall Rivastigmine Tartrate
View Recall Number, Date, Reasons, Quantity
FDA Recall Enforcement Reports
The last Recall Enforcement Report for Rivastigmine Tartrate with NDC 55111-354 was initiated on 03-06-2017 as a Class III recall due to cross-contamination with other products -related substances test for rivastigmine tartrate capsules usp, 1.5 mg showed a peak for ranitidine. The latest recall number for this product is D-0649-2017 and the recall is currently terminated as of 12-21-2017 .
| Recall Number | Initiation Date | Report Date | Recall Classification | Product Quantity | Product Description | Status |
|---|---|---|---|---|---|---|
| D-0649-2017 | 03-06-2017 | 04-12-2017 | Class III | 1,728 bottles | RIVASTIGMINE Tartrate Capsules, USP, 1.5 mg, 60-count bottle, Rx Only, Mfd. By: Dr. Reddy's Laboratories Limited, Bachupally 500-900 India, NDC 55111-352-60 | Terminated |
| D-1325-2015 | 08-03-2015 | 08-19-2015 | Class II | 2,952 bottles | Rivastigmine Tartrate Capsules, USP 1.5 mg, 60 count bottle, Rx Only, Mfd. By Dr. Reddy's Laboratories Limited, Bachupally, India, NDC 55111-352-60 | Terminated |
What is the Enforcement Report?
All drug recalls are monitored by the Food and Drug Administration (FDA) and are included in the Enforcement Report once they are properly classified. The FDA will determine if a firm's removal or correction actions of a marked product meet the requirements to be considered a "recall". The FDA will also determine the public hazard assessment and a recall classification will be published in the Enforcement Report.